This dispute highlights an insurer’s illegal attempt to short-settle a valid ₹6,50,000 robotic surgery claim using hidden internal sub-limits. By leveraging IRDAI regulations that standardize modern treatments and filing a strong challenge under the Consumer Protection Act, the arbitrary capping was successfully overturned. The DCDRC enforced the principles of transparent disclosure, resulting in a complete financial recovery for the policyholder.
Case Snapshot
| Parameter | Details |
| Claim Amount | ₹6,50,000 |
| Cover Amount | ₹15,00,000 |
| Diagnosis | Localized Prostate Cancer (Malignant Neoplasm) |
| Rejection Reason | Capped under “Advanced/Experimental Treatment” clause |
| Forum | Consumer Disputes Redressal Commission (DCDRC) |
| Outcome | Repudiation Overturned; Full Recovery Approved |
| Resolution Time | 11 Months |
Background
The insured had maintained a comprehensive family health plan for over seven continuous years without a break. Upon being diagnosed with prostate cancer, the attending uro-oncologist advised a robotic-assisted surgical approach. This method was chosen specifically for its high precision, reduced blood loss, and significantly lower post-operative morbidity.
Unique Information / Rejection Reason
Despite holding a massive ₹15 Lakhs cover, the insurer processed only ₹1,50,000. The Third Party Administrator (TPA) invoked an obscure policy clause capping “experimental or unproven modern treatments.” They falsely categorized a widely accepted standard robotic surgery under this restrictive umbrella to minimize their payout.
Documents Reviewed
- Original Policy Wordings: Audited to check for explicit, legally valid sub-limits on robotic procedures.
- Treating Doctor’s Certificate: Reviewed for detailed clinical justification of the robotic approach over traditional open surgery.
- Hospital Operative Notes: Analyzed to confirm the standard nature of the surgical protocol utilized.
- TPA Settlement Letter: Scrutinized to map the exact regulatory violations in their deduction logic.
Legal Analysis / Why the Rejection Was Challenged
IRDAI’s standardization guidelines expressly include robotic surgeries under payable “modern treatments.” The insurer failed to present any medical evidence proving the procedure was “experimental.” Furthermore, any restrictive sub-limits applied were not visibly declared in the primary policy schedule provided to the consumer, directly violating the IRDAI (Protection of Policyholders’ Interests) Regulations.
Strategy Adopted & Outcome
A comprehensive legal complaint was filed with the DCDRC, annexing the IRDAI circulars and the surgeon’s medical justification. We argued that denying the operational cost difference constituted an unfair trade practice and a severe deficiency in service. The Commission agreed, noting the insurer’s blatant violation of IRDAI directives, and ordered immediate full settlement of the deducted amount along with strict penalties.
FAQs
1. Can my health insurance deny a robotic surgery claim by calling it “experimental”?
No. IRDAI has explicitly listed robotic surgeries as approved modern treatments. If the procedure is medically necessary and follows standard clinical protocol, an insurer cannot legally reject it as experimental.
2. Are there sub-limits applied to robotic surgeries?
Some insurance policies do apply specific sub-limits to modern treatments. However, Indian consumer law dictates that these financial caps must be clearly defined and highlighted in your policy schedule; hidden caps applied at the time of claim are illegal.
3. What documents do I need to ensure my robotic surgery claim is approved?
Always secure a detailed “Letter of Medical Necessity” from your treating surgeon. This document must explicitly explain why the robotic method is clinically superior or strictly required over traditional open surgery for your specific diagnosis.
4. Can an insurer force me to undergo traditional open surgery instead?
Absolutely not. The choice of treatment methodology lies strictly between the patient and the qualified medical practitioner. Insurers cannot dictate clinical pathways or force older, riskier surgical methods merely to save on claim costs.
Leave a Reply